Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring.

STUDY OBJECTIVE

To determine if one commercial extended-release formulation of nifedipine (Adalat CC) is as effective as another (procardia XL) in controlling blood pressure over 24 hours.

DESIGN

Open-label, randomized, crossover study.

SETTING

University-affiliated family medicine clinic.

PATIENTS

Fifteen patients with stage 1-4 primary hypertension.

INTERVENTIONS

Procardia XL or Adalat CC once/day was titrated to achieve blood pressure control. The effective dose was continued for 4 weeks, washed out for 1 week, and reinstituted with other study drug.

MEASUREMENTS AND MAIN RESULTS

Twenty-four-hour ambulatory blood pressure was recorded the conclusion of each treatment phase. Treatment phases were compared for mean 24-hour blood pressure, mean daytime (6:00 A.M.-10:00 P.M.) and mean nighttime blood pressure, and mean blood pressure load (percentage of blood pressure measurements > 140/90 mm Hg daytime and > 120/80 mm Hg nighttime). Thirteen patients completed the study. No statistically significant difference was seen in mean 24-hour blood pressure (138/86 mm Hg for Procardia XL vs 137/85 mm Hg for Adalat CC), daytime or nighttime blood pressure, or blood pressure load. Two patients experienced clinically significant adverse effects while taking Adalat CC.

CONCLUSIONS

In these patients with primary hypertension, Adalat CC was as effective as Procardia XL at controlling blood pressure for 24 hours. Blood pressure, heart rate, and adverse effects should be monitored 2-4 weeks after any exchange of Adalat CC for Procardia XL.